Literature DB >> 18987151

Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Madhumita Mahalanabis1, Pushpa Jayaraman, Toshiyuki Miura, Florencia Pereyra, E Michael Chester, Barbra Richardson, Bruce Walker, Nancy L Haigwood.   

Abstract

We assessed differences in the character and specificity of autologous neutralizing antibodies (ANAbs) against individual viral variants of the quasispecies in a cohort of drug-naïve subjects with long-term controlled human immunodeficiency virus type 1 (HIV-1) infection and moderate levels of broad heterologous neutralizing antibodies (HNAb). Functional plasma virus showed continuous env evolution despite a short time frame and low levels of viral replication. Neutralization-sensitive variants dominated in subjects with intermittent viral blips, while neutralization-resistant variants predominated in elite controllers. By sequence analysis of this panel of autologous variants with various sensitivities to neutralization, we identified more than 30 residues in envelope proteins (Env) associated with resistance or sensitivity to ANAbs. The appearance of new sensitive variants is consistent with a model of continuous selection and turnover. Strong ANAb responses directed against autologous Env variants are present in long-term chronically infected individuals, suggesting a role for these responses in contributing to the durable control of HIV replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987151      PMCID: PMC2612349          DOI: 10.1128/JVI.01328-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Multiple sequence alignment with the Clustal series of programs.

Authors:  Ramu Chenna; Hideaki Sugawara; Tadashi Koike; Rodrigo Lopez; Toby J Gibson; Desmond G Higgins; Julie D Thompson
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment.

Authors:  Sudhir Kumar; Koichiro Tamura; Masatoshi Nei
Journal:  Brief Bioinform       Date:  2004-06       Impact factor: 11.622

3.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

7.  Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.

Authors:  Susan Moir; Kisani M Ogwaro; Angela Malaspina; Joshua Vasquez; Eileen T Donoghue; Claire W Hallahan; Shuying Liu; Linda A Ehler; Marie A Planta; Shyamasundaran Kottilil; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

8.  Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS.

Authors:  G Scarlatti; T Leitner; V Hodara; M Jansson; A Karlsson; J Wahlberg; P Rossi; M Uhlén; E M Fenyö; J Albert
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

9.  Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

Authors:  D C Montefiori; G Pantaleo; L M Fink; J T Zhou; J Y Zhou; M Bilska; G D Miralles; A S Fauci
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

10.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.

Authors:  Juthathip Mongkolsapaya; Wanwisa Dejnirattisai; Xiao-ning Xu; Sirijitt Vasanawathana; Nattaya Tangthawornchaikul; Aroonrung Chairunsri; Siraporn Sawasdivorn; Thaneeya Duangchinda; Tao Dong; Sarah Rowland-Jones; Pa-thai Yenchitsomanus; Andrew McMichael; Prida Malasit; Gavin Screaton
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

View more
  69 in total

1.  Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Authors:  Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 2.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

4.  HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Authors:  Nicole A Doria-Rose
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

Review 5.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

6.  Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.

Authors:  Rajesh Abraham Jacob; Fatima Abrahams; Marcel Tongo; Michael Schomaker; Paul Roux; Eitel Mpoudi Ngole; Wendy A Burgers; Jeffrey R Dorfman
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

Review 7.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

8.  Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

Authors:  James K Coleman; Ruiyu Pu; Marcus M Martin; Ezra N Noon-Song; Raphael Zwijnenberg; Janet K Yamamoto
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

9.  Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Authors:  María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

10.  Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells.

Authors:  David J Riedel; Mohammad M Sajadi; Cheryl L Armstrong; Jean-Saville Cummings; Cristiana Cairo; Robert R Redfield; C David Pauza
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.